Sp768
HOW SHOULD PCABS BE POSITIONED IN MANAGEMENT OF FOREGUT DISEASE?
Date
May 20, 2024
Tracks
Related Products
FDA Town Hall
SOCIETY: AGA The AGA-FDA Town Hall provides health care professionals, clinical trial investigators, and other interested stakeholders an opportunity to hear directly from FDA representatives about the agency's thinking behind recent approvals, safety signals, guidance documents, and boxed warnings…
CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES A PRO-STEATOTIC AND PRO-INFLAMMATORY METABOLIC STATE IN LIVER
BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…